All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA grants gilteritinib Fast Track Designation for the treatment of R/R AML

By Cynthia Umukoro

Share:

Oct 12, 2017


On 10th October 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to gilteritinib, a Fms Like Tyrosine Kinase 3 (FLT3) inhibitor, for the treatment of adult patients with FLT3 mutation positive (FLT3+) Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1 This comes after the recent Orphan Drug Designation for gilteritinib granted by the FDA in July 2017.

Gilteritinib is a potent, oral FLT3/AXL inhibitor, which binds to and inhibits both the wild-type and mutated forms of FLT3. Data from a phase I/II dose escalation study (NCT02421939), which was published in Lancet Oncology (as reported by the AGP) revealed that gilteritinib monotherapy was well tolerated and generated frequent, prolonged, clinically important responses in FLT3 mutated patients with R/R AML.2 Additionally in an interview with the AGP,  Alexander E. Perl from the Abramson Comprehensive Cancer Center, University of Pennsylvania said that gilteritinib showed “limited efficacy in patients that did not have FLT3 mutations suggesting that this agent is highly selective in its activity against the FLT3 inhibition”.

Presently, gilteritinib is being explored in multiple studies including the phase III ADMIRAL study (NCT02421939), which is assessing oral gilteritinib 120 mg/day in R/R AML patients with FLT3 mutations after first-line therapy.

References